Church of England considers holy communion options for gluten-intolerant
Earlier this year the Church issued a statement to clarify it was not banning gluten-free bread or non-alcoholic communion wine, following a widely-reported question asked ahead of its February General Synod.
That question noted that under Church law the use of wheat alternatives for communion bread such as rice or potato flour 'are prohibited' and that communion wine would always have at least a residual alcohol content.
Asker Reverend Canon Alice Kemp described it as an 'injustice' that some people could therefore not partake in communion.
Holy communion is one of the central sacraments of the Christian faith, with the bread and wine given to the congregation symbolising the body and blood of Christ.
The Church confirmed gluten-free bread or non-alcoholic wine is routinely offered at churches across the country, noting that many professional ecclesiastical suppliers have long provided wine or bread 'which may contain tiny traces of alcohol or gluten which can legitimately be considered non-alcoholic or gluten-free'.
Ahead of this month's Synod, another member asked what progress had been made on ensuring people who are unable to consume gluten or alcohol 'in even trace amounts' can receive holy communion.
Bishop of Lichfield, the Right Reverend Dr Michael Ipgrave, said those who 'cannot physically receive the sacrament (including those who may have an allergy or intolerance to one or both elements) are to be assured that they are partakers by faith of the body and blood of Christ and of the benefits he conveys to us by them'.
He added that the accessible liturgy working group is looking at providing guidance for best practice in the administration of holy communion and considering the specific case of someone who cannot consume even trace amounts of gluten or alcohol 'and the theological, liturgical, and legal basis for the teaching of the Church of England on this matter'.
Synod – known as the Church's parliament – will run from Friday to Tuesday.
It will, in a rare occurrence, hear from a senior military figure on Friday afternoon.
Brigadier Jaish Mahan, a Christian who served in Kosovo, Sierra Leone, Iraq and Afghanistan, will address Synod members on the current global climate and the challenges for the UK, as well as speaking of his own experience in the military.
It comes after the Church confirmed it is preparing for how it might respond should 'serious conflict' break out, including looking back to the leadership shown by senior religious figures during the Second World War.
Legislative changes are due to be brought before Synod, which would allow Armed Forces chaplains, when operating in their roles, to minister under an Archbishops' licence without also having to hold diocesan PTO (permission to officiate).
The current rules add a serious administrative burden and make it more difficult for chaplains to deploy within the UK at the pace required by their roles, a Synod paper states.
Hashtags

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles


Washington Post
an hour ago
- Washington Post
There's no vaccine for this
The simplified, somewhat apocryphal story I was taught about the origins of vaccines is this one: In 1796, at the height of the smallpox epidemic, physician Edward Jenner noticed that milkmaids who had contracted cowpox, a related but milder illness, appeared to be immune to the more severe disease, which killed 30 percent of the people who caught it. Jenner took a cowpox sample from an infected milkmaid and injected it into the arm of a willing subject, and the subject became immune, and smallpox became eradicated, and we never looked back.
Yahoo
2 hours ago
- Yahoo
Market Surges Amid Rising Liver Disease and Cancer Prevalence
The global ascites market is experiencing significant growth, driven by the rising prevalence of liver diseases, cancers, and other risk factors like alcohol consumption and hepatitis infections. Key advancements in diagnostic technologies, such as ultrasound and CT scans, are enhancing early detection and treatment options. Despite growth, challenges like high treatment costs and potential side effects hinder market expansion, particularly in developing regions. Leading companies, including Ocelot Bio and Regeneron Pharmaceuticals, are innovating to improve treatment efficacy. With increasing demand in emerging markets and an aging population, the ascites market is set for sustained growth. Dublin, July 14, 2025 (GLOBE NEWSWIRE) -- The "Ascites Market - A Global and Regional Analysis: Focus on Regional and Country Analysis - Analysis and Forecast, 2025-2035" report has been added to ascites market is witnessing substantial growth, driven by a range of key factors. One of the primary drivers for the ascites market is the rising prevalence of liver diseases, particularly cirrhosis, as well as various forms of cancer, such as liver, ovarian, and pancreatic cancer. As these diseases are among the leading causes of ascites, their increasing incidence globally is driving the demand for diagnostic tools and treatment options. The global rise in lifestyle diseases, alcohol consumption, and hepatitis infections has contributed to this increase, which in turn propels the growth of the ascites market. As the ascites market continues to evolve, several emerging trends are expected to significantly influence its future trajectory. The aging global population is another significant factor driving the ascites market. Older adults are more prone to liver diseases, heart failure, and cancer, all of which are major risk factors for ascites. As the number of elderly individuals increases, the prevalence of ascites is expected to rise, further driving the demand for effective treatments and management strategies. Leading players in the global ascites market, such as Ocelot Bio, Regeneron Pharmaceuticals, and BioVie Inc., are continuously focusing on several strategies to maintain their competitive edge and drive growth. These strategies include continuous technological innovation, such as the development of more advanced and efficient treatment options, mapping systems, and imaging technologies. These companies aim to enhance the safety and efficacy of ascites treatment competitive landscape of the global ascites market is diverse, with numerous players across different regions offering a wide range of products. Regional players and local manufacturers are expected to play an important role in the market's growth, especially as demand increases in emerging markets such as Asia-Pacific and Latin America. As consumer preferences shift towards more discreet, comfortable, and affordable solutions, the ascites market will continue to evolve, fostering new opportunities for both established and emerging the development and improvement of diagnostic technologies, including imaging techniques like ultrasound, CT scans, and the use of paracentesis for fluid analysis, are major drivers for the ascites market. Early detection and accurate diagnosis allow for timely intervention, improving treatment outcomes. The availability of non-invasive and highly sensitive diagnostic tests increases the likelihood of diagnosing ascites in its early stages, expanding the demand for related treatment and management the positive growth trajectory, several challenges continue to impact the global ascites market. One of the primary challenges is the high cost of treatments, particularly for advanced interventions such as liver transplants, chemotherapy, and some novel drug therapies. These costs can be a significant barrier to access, especially in developing regions where healthcare infrastructure may be limited, and insurance coverage for expensive treatments may not be available. This high cost can restrict the market growth, as many patients may not be able to afford the necessary side effects and complications of treatment further restrict the market growth. Several treatments for ascites, including diuretics and paracentesis, can lead to complications or side effects, such as electrolyte imbalances, infections, or low blood pressure. These potential risks may deter patients from seeking treatment or adhering to prescribed regimens, thus limiting the overall demand for these interventions. Additionally, the invasive nature of some treatments, such as the need for repeated paracentesis, can be uncomfortable for patients and may result in decreased willingness to pursue these conclusion, the global ascites market is expected to see steady growth, driven by the increasing prevalence of underlying conditions such as liver diseases and cancers, as well as advancements in diagnostic and therapeutic options. Continued research and innovation in targeted treatments, along with a growing focus on early detection, will be key to improving patient outcomes and reducing the burden of ascites on healthcare systems. As stakeholders, including pharmaceutical companies, healthcare providers, and researchers, continue to work toward better management strategies, the market will evolve to offer more effective solutions, ultimately enhancing the quality of life for patients and addressing the ongoing challenges posed by this Topics Covered: 1. Global Ascites Markets: Industry Outlook1.1 Introduction1.2 Market Trends1.3 Regulatory Framework1.4 Epidemiology of Ascites1.5 Clinical Trial Analysis1.6 Market Dynamics1.6.1 Impact Analysis1.6.2 Market Drivers1.6.3 Market Challenges1.6.4 Market Opportunities2. Global Ascites Market, by Region, $Million, 2023-20352.1 North America2.1.1 Key Findings2.1.2 Market Dynamics2.1.3 Market Sizing and Forecast2.1.3.1 North America Ascites Market, by Country2.1.3.1.1 U.S.2.2 Europe2.2.1 Key Findings2.2.2 Market Dynamics2.2.3 Market Sizing and Forecast2.2.3.1 Europe Ascites Market, by Country2.2.3.1.1 Germany2.2.3.1.2 U.K.2.2.3.1.3 France2.2.3.1.4 Italy2.2.3.1.5 Spain2.3 Asia Pacific2.3.1 Key Findings2.3.2 Market Dynamics2.3.3 Market Sizing and Forecast2.3.3.1 Asia Pacific Ascites Market, by Country2.3.3.1.1 Japan3. Global Ascites Market: Competitive Landscape and Company Profiles3.1 Key Development and Strategies3.1.1 Mergers and Acquisitions3.1.2 Synergistic Activities3.1.3 Business Expansions and Funding3.1.4 Product Launches and Approvals3.1.5 Other Activities3.2 Company Profiles3.2.1 Ocelot Bio3.2.1.1 Overview3.2.1.2 Top Products / Product Portfolio3.2.1.3 Target Customers/End-Users3.2.1.4 Key Personnel3.2.1.5 Analyst View3.2.2 PharmaIN3.2.3 Grifols Therapeutics LLC.3.2.4 Regeneron Pharmaceuticals.3.2.5 BioVie Inc4. Research Methodology For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Error in retrieving data Sign in to access your portfolio Error in retrieving data Error in retrieving data Error in retrieving data Error in retrieving data
Yahoo
2 hours ago
- Yahoo
Market to Reach $14.34 Billion by 2034, Driven by Innovative R&D, Strategic Collaborations, and Drug Formulation Advancements
The Europe GLP-1 agonists market, valued at USD 7.09 billion in 2024, is set to grow at a 17.30% CAGR, reaching USD 14.34 billion by 2034. Driven by rising diabetes and obesity rates, innovative drug formulations, and supportive healthcare policies, the market is expanding. Key players include Eli Lilly, Sanofi, and Novo Nordisk. Challenges involve high costs and regulatory complexities. Opportunities lie in obesity treatment expansion and advanced drug delivery systems. European Glucagon-like Peptide-1 (GLP-1) Agonists Market Dublin, July 14, 2025 (GLOBE NEWSWIRE) -- The "Europe Glucagon-like Peptide-1 (GLP-1) Agonists Market Report and Forecast 2025-2034" has been added to offering. The Europe glucagon-like peptide-1 (GLP-1) agonists market is projected to witness significant growth, fueled primarily by an increased prevalence of type 2 diabetes and obesity. Originally valued at USD 7.09 billion in 2024, the market is estimated to expand at a compound annual growth rate (CAGR) of 17.30%, expecting a valuation of USD 14.34 billion by 2034. The competitive landscape features major pharmaceutical firms like Novo Nordisk, Eli Lilly, Sanofi, AstraZeneca, and others focused on innovative R&D, strategic collaborations, and drug formulation advancements. These companies aim to enhance market presence through mergers, acquisitions, and partnerships that promote access and compliance, ensuring sustained growth in the Europe's GLP-1 agonists market. The market's expansion is propelled by the increasing incidence of diabetes and obesity, augmented by sedentary lifestyles and poor dietary choices. GLP-1 agonists, as incretin-based therapies, are preferred for their efficacy in controlling blood sugar levels and facilitating weight loss, crucial aspects in managing diabetes and obesity. The growth trajectory is supported by rising healthcare expenditure, a burgeoning elderly demographic, advancements in drug delivery, and a robust regulatory framework favoring novel therapeutic adoption. Key Attributes: Report Attribute Details No. of Pages 300 Forecast Period 2025 - 2034 Estimated Market Value (USD) in 2025 $7.09 Billion Forecasted Market Value (USD) by 2034 $14.34 Billion Compound Annual Growth Rate 7.3% Regions Covered Europe Market Drivers A surge in type 2 diabetes and obesity cases. Favorable government initiatives and reimbursement policies bolstering access to innovative treatments. Improved drug formulations like once-weekly injectables and oral options enhancing patient compliance. A growing trend towards combination therapies integrating GLP-1 agonists for optimized results. Market Challenges High costs of GLP-1 therapies affecting widespread accessibility. Potential side effects that could hinder patient adherence. Regulatory complexities delaying new therapy commercializations. Future Opportunities Expanding applications in obesity treatment beyond diabetes management. Innovative drug delivery system developments heightening market penetration. Strategic R&D investments for next-gen GLP-1 therapies with enhanced efficacy. Europe GLP-1 Agonists Market Trends The shift towards long-acting GLP-1 formulations like once-weekly injections elevating patient compliance. The increasing use of GLP-1 agonists in obesity management, supported by regulatory endorsements. Clinical validation of cardiovascular benefits driving GLP-1 adoption among patients at cardiovascular risk. Policymaker efforts in expanding healthcare coverage improving treatment accessibility. The development of multi-target GLP-1 therapies promises superior management of diabetes and weight issues. Strategic collaborations in biosimilar production broadening market access and affordability. Market Segmentation By Drugs: Key drugs include dulaglutide, exenatide, liraglutide, tirzepatide, lixisenatide, and semaglutide. By Application: The applications span type 2 diabetes mellitus and obesity treatment. By Route of Administration: Dominated by parenteral routes, the market is gradually seeing a rise in oral solution adoption. By End User: Primary users are hospitals, specialty clinics, academic research sites, with home care settings gaining traction. By Distribution Channel: Hospital pharmacies prevail, while retail and online pharmacies steadily gain ground. By Region: The United Kingdom, Germany, France, and Italy emerge as principal markets, bolstered by strong infrastructure and supportive policies. Companies Featured Eli Lilly and Company Sanofi Novo Nordisk A/S AstraZeneca plc For more information about this report visit About is the world's leading source for international market research reports and market data. We provide you with the latest data on international and regional markets, key industries, the top companies, new products and the latest trends. Attachment European Glucagon-like Peptide-1 (GLP-1) Agonists Market CONTACT: CONTACT: Laura Wood,Senior Press Manager press@ For E.S.T Office Hours Call 1-917-300-0470 For U.S./ CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900Sign in to access your portfolio